Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

15.49USD
8 Dec 2017
Change (% chg)

$0.40 (+2.65%)
Prev Close
$15.09
Open
$15.24
Day's High
$15.49
Day's Low
$15.15
Volume
227,220
Avg. Vol
389,537
52-wk High
$19.94
52-wk Low
$13.44

Latest Key Developments (Source: Significant Developments)

Ironwood Pharmaceuticals Strengthens Executive Leadership Team
Tuesday, 28 Nov 2017 08:00am EST 

Nov 28 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM.IRONWOOD PHARMACEUTICALS INC - PROMOTED ‍ GINA CONSYLMAN TO SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.  Full Article

Ironwood Pharma files for potential mixed shelf offering
Thursday, 2 Nov 2017 05:36pm EDT 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​.  Full Article

Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18
Thursday, 2 Nov 2017 08:01am EDT 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Q3 non-GAAP loss per share $0.18.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Ironwood Pharmaceuticals provides third quarter 2017 investor update.Q3 loss per share $0.22.Q3 revenue $87 million versus I/B/E/S view $73.6 million.Ironwood Pharmaceuticals Inc sees 2017 ‍R&D expenses to be in low-to-middle end of previously guided $145 million to $160 million range​.Ironwood Pharmaceuticals Inc - ‍data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017​.Ironwood Pharmaceuticals Inc - ‍to use less than $110 million in cash for operations in 2017, up from less than $100 million previously guided​.Ironwood - sees co & Allergan's ‍combined total 2017 marketing & sales expenses for Linzess in middle of previously guided $250 million to $280 million range​.Ironwood Pharmaceuticals Inc - co & Allergan no longer intend to pursue linaclotide delayed release-1​.  Full Article

Ironwood Pharma says CFO Tom Graney will leave company
Wednesday, 6 Sep 2017 08:00am EDT 

Sept 6 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company.Ironwood Pharmaceuticals Inc - ‍gina Consylman will serve as company's interim chief financial officer​.Ironwood Pharmaceuticals Inc - ‍initiated search for a senior business strategy and finance executive to complement its current leadership team​.  Full Article

Ironwood Pharma announces FDA approval of Duzallo to treat hyperuricemia in patients with uncontrolled gout
Monday, 21 Aug 2017 08:00am EDT 

Aug 21 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals announces FDA approval of Duzallo (Lesinurad And Allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout.Ironwood Pharmaceuticals inc- ‍Ironwood expects Duzallo to be commercially available early in Q4 of 2017​.  Full Article

Ironwood Pharmaceuticals Q2 loss per share $0.30
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals provides second quarter 2017 investor update.Q2 non-GAAP loss per share $0.28.Q2 loss per share $0.30.Q2 revenue $65.1 million versus I/B/E/S view $70.8 million.Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Ironwood Pharmaceuticals - sees ‍combined Allergan, Ironwood total 2017 marketing and sales expenses for Linzess to be in range of $250 million to $280 million​.  Full Article

Ironwood Pharmaceuticals reports Q1 loss per share of $0.36
Monday, 8 May 2017 08:00am EDT 

May 8 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood pharmaceuticals provides first quarter 2017 investor update.Q1 non-gaap loss per share $0.33.Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Q1 loss per share $0.36.Q1 revenue $52.2 million.Q1 revenue view $69.7 million -- Thomson Reuters I/B/E/S.  Full Article

Ironwood pharmaceuticals qtrly loss per share $0.09
Tuesday, 21 Feb 2017 04:01pm EST 

Ironwood Pharmaceuticals Inc : Qtrly loss per share $0.09 . Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million. . Qtrly non-gaap loss per share $0.12 . Ironwood Pharmaceuticals Inc - expects combined allergan and ironwood total 2017 marketing and sales expenses for linzess to be in range of $250 million to $280 million . Q4 earnings per share view $-0.24, revenue view $76.9 million -- Thomson Reuters I/B/E/S .Expects to use less than $100 million in cash for operations in 2017.  Full Article

Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan
Sunday, 29 Jan 2017 07:00pm EST 

Astellas Pharma Inc <4503.T>: Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan . Says Linaclotide is approved in Japan as first prescription treatment for adults with irritable bowel syndrome with constipation . Says patients in phase III cc trial in Japan continue to receive open-label Linaclotide for an additional 52 weeks . Astellas Pharma -top-line trial results indicate that linaclotide-treated patients showed statistically significant improvement compared to placebo-treated patients .Says most common adverse event reported in this trial was diarrhea.  Full Article

U.S. FDA approves 72 mcg dose of linzess® (linaclotide) for adults with chronic idiopathic constipation
Thursday, 26 Jan 2017 07:01am EST 

Allergan Plc : Says new dose is expected to be available in q1 of 2017 .U.S. Food and Drug Administration approves 72 mcg dose of linzess® (linaclotide) for adults with chronic idiopathic constipation.  Full Article

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS